Skip to content Skip to footer
Subscribe Now
PharmaShots Interview In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting
VIEWPOINTS

PharmaShots Interview: In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting

Shots: Richard spoke about the results from the Phase 1 AURELIO-03 study of IL-15 superagonist Richard also emphasized the clinical benefits of the IL-15 superagonist when combined with pembrolizumab The interview gives a profound understanding of the existing & developing cancer therapies as treatment options for solid tumors Smriti: Explain the details (MOA, ROA, formulations, etc.)…
June 22, 2022

Read more

PharmaShots Interview SOTIO Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced Metastatic Solid Tumors
VIEWPOINTS

PharmaShots Interview: SOTIO’ Richard Sachse Shares Insight on SOT101 for the Treatment of Advanced/Metastatic Solid Tumors

In an interview with PharmaShots, Richard Sachse, Chief Medical Officer & Managing Director at SOTIO shared his views on the data of SOT101 in the P-I/Ib (AURELIO-03) study for the treatment of advanced/metastatic solid tumors Shots: The P-I/Ib (AURELIO-03) study evaluates SOT101 as monothx. & in combination with pembrolizumab in patients with advanced/metastatic solid tumors The results showed that 13 patients…
April 6, 2022

Read more